| Name
|
Amylin (1-13), human
|
| Code
|
[198328-30-2]
|
| The alias
|
Amylin (1-13), human
|
| Sequence (single letter abbreviation)
|
KCNTATCATQRLA (Cys2 and 7 bridge)
|
| Sequence (three-letter abbreviation)
|
H-Lys-Cys-Asn-Thr-Ala-Thr-Cys-Ala-Thr-Gln-Arg-Leu-Ala-OH (trifluoroacetate salt)(Cys2 and 7 bridge)
|
| A basic description
|
Amylin (8-37) is a truncated analog of native Amylin that selectively inhibits insulin-related glucose uptake and glycogen deposition in muscle tissue. The peptide has a systemic increase in insulin sensitivity and has shown to reduce basal insulin levels in both normal and hGH-induced insulin-resistant rats.
|
| solubility
|
|
| The molecular weight
|
1378.6
|
| Chemical formula
|
C54H95N19O19S2
|
| The purity
|
80%，90%，95%，98%，99%
|
| Weight
|
1mg,5mg,10mg,50mg,100mg,1g
|
| Storage conditions
|
Store at -20°C. Keep tightly closed. Store in a cool dry place.
|
| Annotation
|
|
| Documents
|
|
| Figures
|
|
| Reference
|
D.Radovan et al., Biochemistry, 47, 6352 (2008)
|
| The C-terminal
|
|
| The N-terminal
|
|
| Chemical bridge
|
(Cys2 and 7 bridge)
|